• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Breast Cancer Recurrence Risks Following Endocrine Therapy – 20 Years Out

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • 5 year adjuvant endocrine treatment substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer
  • Tamoxifen reduces recurrence rates by approximately 50% during the first 5 treatment years and 30% during the next 5 years
  • Extended treatment past 5 years is correlated with additional side effects
  • Hongchao et al. (NEJM, 2017) sought to determine the impact of various characteristics of the original tumor on the 20-year incidence of breast cancer outcomes among women who received adjuvant endocrine therapy for 5 years
  • The main goal of the study was to identify subgroups of women who may be at such low risk for recurrence after stopping endocrine therapy that risks of continuing such therapy would outweigh benefits

METHODS:

  • Meta-analysis
    • 88 trials in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database of randomized trials
    • Inclusion: Women with ER-positive breast cancer disease-free after 5 years of scheduled endocrine therapy (tamoxifen or aromatase inhibitor)
    • T1 disease (tumor diameter, ≤2.0 cm) or T2 disease (tumor diameter, >2.0 to 5.0 cm)
    • < 10 involved nodes (no nodes [N0]; 1 to 3 nodes [N1–3]; or 4 to 9 nodes [N4–9])
    • No metastases
  • Primary outcomes
    • Rate of distant recurrence regardless of any local or contralateral events
    • Rate of any breast-cancer event (distant recurrence, locoregional recurrence, or contralateral new primary tumor)
    • Rate of death from breast cancer

RESULTS:

  • 62,923 women in 88 trials were still being followed at 5 years without recurrence or a second cancer
  • Breast cancer recurrence continued at a steady rate throughout the study period from 5 to 20 years
  • Women with stage T1 disease: Risk of distant recurrence was
    • 13% with no nodal involvement (T1N0)
    • 20% with one to three nodes involved (T1N1–3)
    • 34% with four to nine nodes involved (T1N4–9)
  • Women with stage T2 disease, the risk of distant recurrence was
    • 19% with T2N0
    • 26% with T2N1–3
    • 41% with T2N4–9
  • TN status was correlated with higher risk of death from breast cancer, but not with higher risk of contralateral breast cancer
  • Given the TN status, tumor grade (available in 43,590 patients) and Ki-67 marker status (available in 7692 patients) were of only of moderate independent predictive value for distant recurrence
  • Progesterone receptor (in 54,115 patients) and human epidermal growth factor receptor type 2 (HER2) status were not predictive
  • During the study period from 5 to 20 years, the absolute risk of distant recurrence among patients with T1N0 breast cancer was 10% for low-grade disease, 13% for moderate-grade disease, and 17% for high-grade disease
  • Risks of any recurrence or a contralateral breast cancer were 17% for low-grade disease, 22% for moderate-grade disease and 26% for high-grade disease

CONCLUSION:

  • After 5 years of adjuvant endocrine therapy, breast-cancer recurrences continued to occur steadily throughout the study period from 5 to 20 years in women with ER-positive, early-stage breast cancer
  • There was a high correlation with TN status and distant recurrence
  • Knowledge of risks may guide risk prevention strategies, such as extending endocrine therapy

Learn More – Primary Sources:

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

BRCA1 & BRCA2 Mutations: What Are the Risks for Developing Breast and Ovarian Cancer?
Prophylactic Mastectomy and BRCA – Risk Reduction and Guidelines
Mammography Guidelines for Average-Risk Women

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site